SEC Form 4 · accession 0001250853-18-000134
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Denise Bevers
Officer — President and COO · Director
Period of report
Oct 22, 2018
Accepted (ET)
Oct 24, 2018 · 8:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.60 | Oct 22, 2018 | A | 75,000 | A | — | Oct 22, 2028 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1The option will vest as to 25% after one year following the date of grant, and the remainder will vest in equal monthly installments over the following three years.